A detailed history of Artal Group S.A. transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Artal Group S.A. holds 2,779,619 shares of SLN stock, worth $50.2 Million. This represents 3.35% of its overall portfolio holdings.

Number of Shares
2,779,619
Previous 2,779,619 -0.0%
Holding current value
$50.2 Million
Previous $60 Million 12.04%
% of portfolio
3.35%
Previous 3.24%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$17.39 - $26.25 $3.83 Million - $5.79 Million
-220,381 Reduced 7.35%
2,779,619 $60 Million
Q4 2023

Feb 09, 2024

BUY
$6.7 - $17.67 $3.35 Million - $8.84 Million
500,000 Added 20.0%
3,000,000 $52.1 Million
Q3 2023

Nov 13, 2023

BUY
$5.07 - $10.74 $4.06 Million - $8.59 Million
800,000 Added 47.06%
2,500,000 $24.6 Million
Q2 2023

Aug 11, 2023

BUY
$4.61 - $7.44 $5.51 Million - $8.89 Million
1,194,926 Added 236.58%
1,700,000 $9.35 Million
Q1 2023

May 12, 2023

BUY
$6.2 - $15.61 $3.13 Million - $7.88 Million
505,074 New
505,074 $3.13 Million

Others Institutions Holding SLN

About Silence Therapeutics plc


  • Ticker SLN
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,888,400
  • Market Cap $649M
  • Description
  • Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...
More about SLN
Track This Portfolio

Track Artal Group S.A. Portfolio

Follow Artal Group S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.